BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

425 related articles for article (PubMed ID: 33039207)

  • 1. The reporting sensitivity of the Vaccine Adverse Event Reporting System (VAERS) for anaphylaxis and for Guillain-Barré syndrome.
    Miller ER; McNeil MM; Moro PL; Duffy J; Su JR
    Vaccine; 2020 Nov; 38(47):7458-7463. PubMed ID: 33039207
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Signals and trends of Guillain-Barré syndrome after the introduction of live-attenuated vaccines for influenza in the US and South Korean adverse event reporting systems.
    Lee H; Kim HJ; Choe YJ; Shin JY
    Vaccine; 2020 Jul; 38(34):5464-5473. PubMed ID: 32600907
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adverse events following pandemic influenza A (H1N1) 2009 monovalent and seasonal influenza vaccinations during the 2009-2010 season in the active component U.S. military and civilians aged 17-44years reported to the Vaccine Adverse Event Reporting System.
    Bardenheier BH; Duderstadt SK; Engler RJ; McNeil MM
    Vaccine; 2016 Aug; 34(37):4406-14. PubMed ID: 27449076
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Surveillance for safety after immunization: Vaccine Adverse Event Reporting System (VAERS)--United States, 1991-2001.
    Zhou W; Pool V; Iskander JK; English-Bullard R; Ball R; Wise RP; Haber P; Pless RP; Mootrey G; Ellenberg SS; Braun MM; Chen RT
    MMWR Surveill Summ; 2003 Jan; 52(1):1-24. PubMed ID: 12825543
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prediction of post-vaccination Guillain-Barré syndrome using data from a passive surveillance system.
    Luo C; Jiang Y; Du J; Tong J; Huang J; Lo Re V; Ellenberg SS; Poland GA; Tao C; Chen Y
    Pharmacoepidemiol Drug Saf; 2021 May; 30(5):602-609. PubMed ID: 33533072
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Guillain-Barré syndrome following influenza vaccination.
    Haber P; DeStefano F; Angulo FJ; Iskander J; Shadomy SV; Weintraub E; Chen RT
    JAMA; 2004 Nov; 292(20):2478-81. PubMed ID: 15562126
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Monitoring the safety of high-dose, trivalent inactivated influenza vaccine in the vaccine adverse event reporting system (VAERS), 2011 - 2019.
    Moro PL; Woo EJ; Marquez P; Cano M
    Vaccine; 2020 Aug; 38(37):5923-5926. PubMed ID: 32709434
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety of influenza A (H1N1) 2009 monovalent vaccines - United States, October 1-November 24, 2009.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2009 Dec; 58(48):1351-6. PubMed ID: 20010511
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Surveillance of adverse events after the first trivalent inactivated influenza vaccine produced in mammalian cell culture (Flucelvax(®)) reported to the Vaccine Adverse Event Reporting System (VAERS), United States, 2013-2015.
    Moro PL; Winiecki S; Lewis P; Shimabukuro TT; Cano M
    Vaccine; 2015 Nov; 33(48):6684-8. PubMed ID: 26518405
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influenza vaccination and Guillain Barre syndrome.
    Geier MR; Geier DA; Zahalsky AC
    Clin Immunol; 2003 May; 107(2):116-21. PubMed ID: 12763480
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adverse events following adenovirus type 4 and type 7 vaccine, live, oral in the Vaccine Adverse Event Reporting System (VAERS), United States, October 2011-July 2018.
    McNeil MM; Paradowska-Stankiewicz I; Miller ER; Marquez PL; Seshadri S; Collins LC; Cano MV
    Vaccine; 2019 Oct; 37(44):6760-6767. PubMed ID: 31548014
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Post-licensure surveillance of trivalent live attenuated influenza vaccine in adults, United States, Vaccine Adverse Event Reporting System (VAERS), July 2005-June 2013.
    Haber P; Moro PL; McNeil MM; Lewis P; Woo EJ; Hughes H; Shimabukuro TT
    Vaccine; 2014 Nov; 32(48):6499-504. PubMed ID: 25258101
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Guillain-Barré syndrome after H1N1 vaccination in the United States: a report using the CDC/FDA Vaccine Adverse Event Reporting System (2009).
    Souayah N; Yacoub HA; Khan HM; Michas-Martin PA; Menkes DL; Maybodi L; Qureshi AI
    Neuroepidemiology; 2012; 38(4):227-32. PubMed ID: 22555646
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Post-licensure surveillance of quadrivalent inactivated influenza (IIV4) vaccine in the United States, Vaccine Adverse Event Reporting System (VAERS), July 1, 2013-May 31, 2015.
    Haber P; Moro PL; Lewis P; Woo EJ; Jankosky C; Cano M
    Vaccine; 2016 May; 34(22):2507-12. PubMed ID: 27015735
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Postlicensure safety surveillance for high-dose trivalent inactivated influenza vaccine in the Vaccine Adverse Event Reporting System, 1 July 2010-31 December 2010.
    Moro PL; Arana J; Cano M; Menschik D; Yue X; Lewis P; Haber P; Martin D; Broder K
    Clin Infect Dis; 2012 Jun; 54(11):1608-14. PubMed ID: 22441652
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A cluster of nonspecific adverse events in a military reserve unit following pandemic influenza A (H1N1) 2009 vaccination-possible stimulated reporting?
    McNeil MM; Arana J; Stewart B; Hartshorn M; Hrncir D; Wang H; Lamias M; Locke M; Stamper J; Tokars JI; Engler RJ
    Vaccine; 2012 Mar; 30(14):2421-6. PubMed ID: 22310205
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Absence of associations between influenza vaccines and increased risks of seizures, Guillain-Barré syndrome, encephalitis, or anaphylaxis in the 2012-2013 season.
    Kawai AT; Li L; Kulldorff M; Vellozzi C; Weintraub E; Baxter R; Belongia EA; Daley MF; Jacobsen SJ; Naleway A; Nordin JD; Lee GM
    Pharmacoepidemiol Drug Saf; 2014 May; 23(5):548-53. PubMed ID: 24497128
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association between Guillain-Barré syndrome and influenza A (H1N1) 2009 monovalent inactivated vaccines in the USA: a meta-analysis.
    Salmon DA; Proschan M; Forshee R; Gargiullo P; Bleser W; Burwen DR; Cunningham F; Garman P; Greene SK; Lee GM; Vellozzi C; Yih WK; Gellin B; Lurie N;
    Lancet; 2013 Apr; 381(9876):1461-8. PubMed ID: 23498095
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Post-licensure safety surveillance of zoster vaccine live (Zostavax®) in the United States, Vaccine Adverse Event Reporting System (VAERS), 2006-2015.
    Miller ER; Lewis P; Shimabukuro TT; Su J; Moro P; Woo EJ; Jankosky C; Cano M
    Hum Vaccin Immunother; 2018; 14(8):1963-1969. PubMed ID: 29580194
    [TBL] [Abstract][Full Text] [Related]  

  • 20. International collaboration to assess the risk of Guillain Barré Syndrome following Influenza A (H1N1) 2009 monovalent vaccines.
    Dodd CN; Romio SA; Black S; Vellozzi C; Andrews N; Sturkenboom M; Zuber P; Hua W; Bonhoeffer J; Buttery J; Crawford N; Deceuninck G; de Vries C; De Wals P; Gutierrez-Gimeno MV; Heijbel H; Hughes H; Hur K; Hviid A; Kelman J; Kilpi T; Chuang SK; Macartney K; Rett M; Lopez-Callada VR; Salmon D; Gimenez-Sanchez F; Sanz N; Silverman B; Storsaeter J; Thirugnanam U; van der Maas N; Yih K; Zhang T; Izurieta H;
    Vaccine; 2013 Sep; 31(40):4448-58. PubMed ID: 23770307
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.